'The group treated with CTCE-9908 had a dramatic decrease (67%) in the number of visible lung nodules due to the cancer spreading when compared to the untreated group.'

Overview

Chemokine Therapeutics Corp. is a biotechnology company developing drugs in the field of chemokines and cytokines, a family of small, soluble proteins, which signal stem cell transport and growth into mature cells. These stem cells are master primitive cells, capable of producing billions of mature cells necessary for repair and regeneration. The Company’s main focus is to develop synthetic versions of chemokines which may have potential applications to address unmet medical needs in cancer, immune deficiencies, vascular disease, and infectious diseases.

Tackling those diseases that still ail the population is where Chemokine Therapeutics is aiming its efforts. A Delaware-based corporation with offices in Vancouver and Manhattan. Chemokine is busy developing peptide-based drugs to treat cancer, cardiovascular and infectious disease, efforts which bore fruit this month with encouraging results from tests of its immune booster compound on healthy volunteers.

At the Vancouver facility, Chemokine Therapeutics designs and tests hundreds of peptides for possible development as drug candidates. Currently, the company has five lead products with two of these candidates already in human trials; for immune system recovery following chemotherapy and, a novel anti-cancer drug designed to prevent the spread of the disease. Peptides based drugs produced by the Company's technology have very high affinity for natural chemokine receptors, a high degree of specificity, and long duration of activity. Natural chemokines are well known to play a key role in the recruitment and trafficking of a variety of infection-fighting immune cells. In addition recent research has shown that chemokines may play an important role in cancer, cardiovascular disease and viral infections.

Chemokine Therapeutics' competitive advantage lies in its ability to design synthetic versions of natural chemokines that play an important role in disease prevention and other physiological disorders. Its peptide therapies are based on compounds containing two or more amino acids linked by the carboxyl group of one amino acid to the amino group of another. The Company has already attracted research collaborations with pharmaceutical giant, Procter and Gamble Pharmaceuticals as well as prestigious institutions such as the National Cancer Institute, Memorial Sloan Kettering Institute in New York and the Walther Cancer Institute in Indiana.

Companies with leading edge technologies present attractive risk/reward opportunities for investors. Chemokine Therapeutics represents only a handful of biotechnology companies with technology that has the potential to exploit chemokine biology, in the war against infectious disease, cancer, cardiovascular disease. But going full-bore with this research entails big capital inflows, which biotechnology companies share, in part, by licensing drugs to larger pharmaceutical companies. Small cap investors willing and able to share some of the risk of that research with the company benefit from helping to fund clinical trials through to the licensing or acquisition stage. A future special report will investigate some of the history of this dynamic company, its recent successes in developing a cancer treatment, along with some of the volatility its stock price has endured of late. Also in this upcoming special report, investors should better understand this new technology and its successes and perhaps be stimulated by what they read to consider backing this exciting new work.

Chemokine Therapeutics has two lead product candidates in clinical trials:

• Chemokines are a recently discovered family of small, soluble proteins, structurally-related to cytokines. They assume a range of important functions in the human body, mainly in relation to the immune system. Among other functions, chemokines are responsible for blood cell formation through stem cell growth and differentiation. In addition, chemokines participate in white blood cell mobilization and in the initiation of immune responses. They are produced and released by a wide variety of cell types.
• In addition to their designated natural functions, chemokines have been found to play an important role in the physiological processes of a variety of prominent and critical diseases. There is a growing focus in the scientific community on chemokine involvement in cancer, both at the level of blood vessel generation and metastasis, in viral infections such as HIV and in autoimmune diseases, as evidenced by studies in an increasing number of research publications and articles.

• Chemokine Therapeutics to Present at Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference (Mon, May 2)
 

• Chemokine Therapeutics' Cancer Compound Highlighted at Major Cancer Conference (Mon Apr. 18)

• Chemokine Therapeutics reports 67% decrease in metastatic nodules with anti-cancer compound (Wed, Mar. 16)
 

Management Team

Hassan Salari, PhD
Chairman, President, & CEO

David L. Karp, CFA, MBA, P.Eng
CFO

Walter Korz, HCA
VP of Drug Development.

Ian Harper, BSc
Director Investor Relations & Corporate Development

Contacts

Vancouver Office:

6190 Agronomy Road
Suite 405
Vancouver, British Columbia,V6T 1Z3
Canada

Telephone: 604.822.0301
Fax: 604.822.0302

SEDAR Filings

CTI filings with SEDAR can be found here. All Fillings are current and the Company is fully reporting.

FORWARD LOOKING STATEMENTS

This report includes forward-looking statements that reflect Chemokine Therapeutics Corp. current expectations about its future results, performance, prospects and opportunities. Chemokine Therapeutics Corp. has tried to identify these forward-looking statements by using words and phrases such as "may," "will," "expects," "anticipates," "believes," "intends," "estimates," "plan," "should," "typical," "preliminary," "we are confident" or similar expressions. These forward-looking statements are based on information currently available and are subject to a number of risks, uncertainties and other factors that could cause Chemokine Therapeutics Corp.'s actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. These risks, uncertainties and other factors include, without limitation, the Company's growth expectations and ongoing funding requirements, and specifically, the Company's growth prospects with scalable customers, and those outlined above. Other risks include the Company's limited operating history, the Company's history of operating losses, consumers' acceptance, the Company's use of licensed technologies, risk of increased competition, the potential need for additional financing, the terms and conditions of any financing that is consummated, the limited trading market for the Company's securities, the possible volatility of the Company's stock price, the concentration of ownership, and the potential fluctuation in the Company's operating results.

AllPennyStocks.com feature stock reports are intended to be stock ideas, NOT recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this report was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. For more information see our disclaimer section, a link of which can be found on our web site. This document contains forward-looking statements, particularly as related to the business plans of the Company, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Actual results may differ materially from the Company's expectations and estimates. This is an advertisement for Chemokine Therapeutics Corp. The purpose of this advertisement, like any advertising, is to provide coverage and awareness for the company. The information provided in this advertisement is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country.

© 1999-2005 AllPennyStocks.com. All rights reserved. AllPennyStocks.com is not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All materials presented on our web site and individual reports released to the public through this web site, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility. Particularly Small-Caps and OTC-BB stocks. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The accuracy or completeness of the information on our web site or within our reports is only as reliable as the sources they were obtained from. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. AllPennyStocks.com may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act of 1933, Section 17(b), AllPennyStocks.com will disclose in it's disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the AllPennyStocks.com web site. AllPennyStocks.com has been compensated seven thousand seven hundred dollars from Chemokine Therapeutics Corp. for its efforts in presenting the CTI profile on its web site and distributing it to its database of subscribers as well as other services. AllPennyStocks.com may decide to purchase or sell shares on a voluntary basis in the open market before, during or after the profiling period of this report. As of the profile date, no shares have been sold. Information presented on our web site and within our reports contain "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “expects’”, “will,” “anticipates,” “estimates, “believes,” or that by statements indicating certain actions “may,” “could,” or “might” occur.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.